Scorpion Therapeutics

Drug Discovery

Scorpion Therapeutics is a private drug discovery company. It has raised $150 million across 3 recorded rounds; the latest was a $150 million Series C in Jul 2024.

PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$150.0M
Last round
Later Stage VC (Series C)
Jul 2024
No prints on record

No secondary trades in Scorpion Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Pro
The prices on Scorpion Therapeutics
  • ·15 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Where Scorpion Therapeutics prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Scorpion Therapeutics stock.